Blocking toxin formation – a treatment for Gram-positive pathogens?
Small molecules that block bacterial toxin formation have shown promise against Gram-positive bacteria in mouse models.
Browsing: Drug Development
The RESTORE-1 trial, results and real world repercussions – an interview with Keith Kaye
In this interview, we speak to to Keith Kaye, Principle Investigator of the RESTORE-1 trial assessing relebactam in combination with imipenem (IMI/REL), about the trial’s results and the implications these have for clinicians in ‘real world’ settings.
Phase III trial suggests meropenem–vaborbactam a valuable option for CRE infection
A Phase III study, TANGO II, has reported that meropenem–vaborbactam monotherapy for CRE infections was associated with improvement in clinical cure rates, lower nephrotoxicity and lower mortality versus best-available therapy.
Novartis and GARDP partner to accelerate the availability of antibiotics for children
GARDP and Novartis have announced a partnership hoping to accelerate the development and availability of generic antibiotics for children in LMICs.
Optimized arylomycins: a new class of Gram-negative antibiotics?
Researchers from Genentech have carried out optimization of the arylomycins, uncovering a molecule with potent, broad-spectrum activity against Gram-negative bacteria.
Drug candidates identified for the prevention of malarial parasite maturation
A team of researchers from Imperial College London (UK) have identified compounds which prevent the malarial parasite sexually maturing inside the mosquito.
Novel non-antibiotic for tuberculosis successfully tested
Scientists at the University of Manchester (UK) have developed the first non-antibiotic drug to successfully…
From TB to leprosy: financial model reveals where pipelines and investments might fall short
Financial modelling has been used to estimate the costs and likelihood of candidate medicines, vaccines, diagnostics and technologies launching, revealing gaps in the pipeline and in funding.
How could 3D printing help combat antibiotic resistance?
From antibiotic susceptibility testing to new instruments to screen for antibiotics, 3D printing is contributing to research on antimicrobial resistance.
US FDA approves first drug for P. vivax treatment in over 50 years
The US FDA have approved Krintafel (tafenoquine) for the radical cure of Plasmodium vivax malaria infections, the first approval for such a drug in 50 years.
